Asha Konde
London, ENG SW36JB, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
PPP2R1A mutations cause ATR inhibitor sensitivity in ovarian clear cell carcinoma.
Journal: Oncogene
Published: June 17, 2024
Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 20, 2024
PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer.
Journal: Cancer research
Published: February 25, 2021
Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.
Journal: PloS one
Published: October 27, 2018
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.
Journal: The Journal of clinical investigation
Published: July 03, 2018
E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.
Journal: Cancer discovery
Published: May 30, 2017
Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.
Journal: PloS one
Published: April 21, 2017
Modeling Therapy Resistance in BRCA1/2-Mutant Cancers.
Journal: Molecular cancer therapeutics
Published: January 30, 2017
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.
Journal: Nature communications
Published: June 15, 2016
Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.
Journal: PloS one
Published: April 19, 2016
CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.
Journal: PloS one
Published: September 21, 2015
Last Updated: 09/26/2026